NAPOLI-3 Study Answers ‘Important Question’ in Metastatic Pancreatic Cancer


An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.

Findings from the phase 3 NAPOLI-3 study (NCT04083235) highlighted improved outcomes following first-line liposomal irinotecan (Onivyde) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) compared with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma, according to Zev A. Wainberg, MD.

CancerNetwork® spoke with lead author, Wainberg, a professor of medicine at the University of California, Los Angeles (UCLA) and co-director of the UCLA Gastrointestinal Oncology Program, regarding data that were presented at the 2023 Gastrointestinal Cancers Symposium, and how they answer an “important question” as to which of the 2 chemotherapy-based regimens were superior.

In the NAPOLI-3 study, the median overall survival was 11.1 months (95% CI, 10.0-12.1) with NALIRIFOX vs 9.2 months (95% CI, 8.3-10.6) with gemcitabine plus nab-paclitaxel (HR, 0.83; 95% CI, 0.71-0.99; P = .04). Additionally, the median PFS was 7.4 months (95% CI, 6.0-7.7) vs 5.6 months (95% CI, 5.3-5.8) in each respective cohort (HR, 0.69; 95% CI, 0.58-0.83; P = .0001).


For many years, we have had 2 regimens that have been used: gemcitabine and nab-paclitaxel being one, and FOLFIRINOX being another. There have not been studies done to compare those 2 [regimens].

This was an attempt to try to answer the question of which was superior. In this case, we used a derivative FOLFIRINOX called NALIRIFOX that uses liposomal irinotecan in place of irinotecan to answer the head-to-head question of which is a superior regimen for the purposes of overall survival.

We enrolled 770 patients with metastatic disease all around the world. The most important efficacy findings were that the NALIRIFOX regimen was superior to gemcitabine plus nab-paclitaxel.

[It] improved overall survival by 1.9 months and improved progression-free survival, as well. [The study] met its end point of improvement in survival over the gemcitabine and nab-paclitaxel regimen. [This trial] answered an important question in the field.


Wainberg ZA, Melisi D, Macarulla T, et al. NAPOLI-3: a randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2023;41(suppl 4):LBA661. doi:10.1200/JCO.2023.41.3_suppl.LBA661

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Sean Dineen, MD, highlights the removal of abdominal wall lesions and other surgical strategies that may help manage symptoms in patients with cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Related Content